Consistently, while treatment with anti-p40 antibodies protected from systemic inflammatory disease and experimental colitis, treatment with anti-p19 alleviated intestinal but did not affect systemic pathology, suggesting a contribution of IL-23 to local inflammation and an IL-12-regulated systemic inflammation (Uhlig et al., 2006[189]). The gene discussed is IL23A; the disease is colitis.